Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)

Int J Clin Oncol. 2022 Apr;27(4):823-824. doi: 10.1007/s10147-022-02118-8.
No abstract available

Publication types

  • Published Erratum